Stability and development of psychotic symptoms and the use of antipsychotic medication - Long-term follow-up

Psychological Medicine

Volumn 47, Issue 12, 2017, Pages 2118-2129

  Gotfredsen, D R ^a   Wils, R S ^a   Hjorthoj, C ^a,b   Austin, S F ^a,c   Albert, N ^a   Secher, R G ^a   Thorup, A A E ^a   Mors, O ^b,c   Nordentoft, M ^a,b  

^a Mental Health Services CPH   (Denmark)

^b Lundbeck Foundation Initiative for Integrative Psychiatric Research   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Key words Schizophrenia; long term outcome.; medication; psychotic illness

Indexed keywords

NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; CLINICAL TRIAL; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PSYCHOSIS; REMISSION; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOTIC DISORDERS; REMISSION INDUCTION; REMISSION, SPONTANEOUS; YOUNG ADULT;

EID: 85017168783     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291717000563     Document Type: Article

References (32)

1. Andreasen N, Carpenter T, Kane J, Robert A, Marder S, Weinberger D (2005). Remission in schizophrenia: proposed criteria and rationale for consensus. American Journal of Psychiatry 162, 441-449.
2. Bertelsen M, Jeppesen P, Petersen L, Thorup A, Øhlenschlaeger J, le Quach P, Christensen TØ, Krarup G, Jørgensen P, NordentoftM(2008). Five-year follow-up of a randomized multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness: the OPUS trial. Archives of General Psychiatry 65, 762-771.
3. Boonstra G, Burger H, Grobbee DE, Kahn R (2011). Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: results from an aborted randomised trial. International Journal of Psychiatry in Clinical Practice 15, 128-134.
4. Cassidy CM, Norman R, Manchanda R, Schmitz N, Malla A (2010). Testing definitions of symptom remission in firstepisode psychosis for prediction of functional outcome at 2 years. Schizophrenia Bulletin 36, 1001-1008.
5. Chen EY, Hui CL, Lam MM, Chiu C, Law CW, Chung DW, Tso S, Chan KT, Yao TJ, Hung SF, Honer WG (2010). Maintenance treatment with quetiapine versus remitted first episode psychosis: randomised controlled trial. British Medical Journal 341, c4024.
6. Ciompi L, Clemens S (1980). Catamnestic long-term study on the course of life and aging of schizophrenics. Schizophrenia Bulletin 6, 606-618.
7. Dold M, Leucht S (2014). Pharmacotherapy of treatmentresistant schizophrenia: a clinical perspective. Evidencebased Mental Health 17, 33-37.
8. Endicott J, Spitzer RL, Fleiss JL, Cohen J (1976). The Global Assessment Scale. A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry 33, 766-771.
9. Fenton WS, Blyler CR, Heinssen RK (1997). Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophrenia Bulletin 23, 637-651.
10. Gitlin M, Nuechterlein K, Subotnik KL, Ventura J, Mintz J, Fogelson DL, Bartzokis G, Aravagiri M (2001). Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. American Journal of Psychiatry 158, 1835-1842.
11. Häfner H, Riecher-Rössler A, Hambrecht M, Maurer K, Meissner S, Schmidtke A, Fätkenheuer B, Löffler W, van der Heiden W (1992). IRAOS: an instrument for the assessment of onset and early course of schizophrenia. Schizophrenia Research 6, 209-223.
12. Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube K, Ganev K, Giel R, an der Heiden W, Holmberg S, Janca A, Lee P, Leon C, Malhotra S, Marsella A, Nakane Y, Sartorius N, Shen Y, Skoda C, Thara R, Tsirkin S, Varma V, Walsh D, Wiersma D (2001). Recovery from psychotic illness: a 15-and 25-year international follow-up study. British Journal of Psychiatry 178, 506-517.
13. Harrow M, Jobe TH (2010). How frequent is chronic multiyear delusional activity and recovery in schizophrenia: a 20-year multi-follow-up. Schizophrenia Bulletin 36, 192-204.
14. Harrow M, Jobe TH, Faull RN (2012). Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime A 20-year longitudinal study. Psychological Medicine 42, 2145-2155.
15. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller H-J (2013). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World Journal of Biological Psychiatry 14, 2-44.
16. Hegelstad WTV, Larsen TK, Auestad B, Evensen J, Haahr U, Joa I, Johannesen JO, Langeveld J, Melle I, Opjordsmoen S, Rossberg JI, Rund BR, Simonsen E, Sundet K, Vaglum P, Friis S, McGlashan T (2012). Long-term follow-up of the TIPS early detection in psychosis study: effects on 10-year outcome. American Journal of Psychiatry 169, 374-380.
17. Hjorthøj CR, Vesterager L, Nordentoft M (2013). Test-retest reliability of the Danish Adult Reading Test in patients with comorbid psychosis and cannabis-use disorder. Nordic Journal of Psychiatry 67, 159-163.
18. Køster A, Lajer M, Lindhardt A, Rosenbaum B (2008). Gender differences in first episode psychosis. Social Psychiatry and Psychiatric Epidemiology 43, 940-946.
19. Leucht S, Pitschel-Walz G, Abraham D, Kissling W (1999). Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research 35, 51-68.
20. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM (2012). Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379, 2063-2071.
21. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M (2013). Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders - A systematic review and meta-analysis. Schizophrenia Bulletin 39, 306-318.
22. Moilanen J, Haapea M, Miettunen J, Jääskeläinen E, Veijola J, Isohanni M, Koponen H (2013). Characteristics of subjects with schizophrenia spectrum disorder with and without antipsychotic medication - A 10-year follow-up of the Northern Finland 1966 Birth Cohort study. European Psychiatry 28, 53-58.
23. Morgan C, Lappin J, Heslin M, Donoghue K, Lomas B, Reininghaus U, Onyejiaka A, Croudace T, Jones PB, Murray RM, Fearon P, Doody GA, Dazzan P (2014). Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 study. Psychological Medicine 44, 2713-2726.
24. Petersen L, Jeppesen P, Thorup A, Abel MB, Øhlenschlaeger J, Christensen TØ, Krarup G, Jørgensen P, Nordentoft M (2005). A randomised multicentre trial of integrated versus standard treatment for patient with a first episode of psychotic illness. British Medical Journal 331, 602.
25. Riecher-Rössler A, Häfner H (2000). Gender aspects in schizophrenia: bridging the border between social and biological psychiatry. Acta Psychiatrica Scandinavica. Supplementum 102, 58-62.
26. Secher RG, Hjorthøj CR, Austin SF, Thorup A, Jeppesen P, Mors O, Nordentoft M (2015). Ten-year follow-up of the OPUS specialized early intervention trial for patients with a first episode of psychosis. Schizophrenia Bulletin 41, 617-626.
27. Takeuchi H, Suzuki T, Uchida H, Watanabe K, Mimura M (2012). Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. Schizophrenia Research 134, 219-225.
28. Wils RS, Gotfredsen DR, Hjorthøj C, Austin SF, Albert N, Secher RG, Thorup AAE, Mors O, Nordentoft M (2016). Antipsychotic medication and remission of psychotic symptoms 10years after a first-episode psychosis. Schizophrenia Research, E-pub ahead of print.
29. Wing J, Babor T, Brugha T, Burke J, Cooper J, Giel R, Jablenski A, Regier D (1990). SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Archives of General Psychiatry 47, 2190539.
30. Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ (2013). Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/ discontinuation or maintenance treatment strategy: longterm follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 70, 913-920.
31. Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D (2007). Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. Journal of Clinical Psychiatry 68, 654-661.
32. Zipursky RB, Menezes NM, Streiner DL (2014). Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophrenia Research 152, 408-414.